Combination therapy targeting KPC-3 (hub) + one peripheral node would exceed monotherapy by removing the bridging gene between resistance clusters
Adversarial Debate Score
54% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
Supporting Research Papers
- The evolutionary trade-offs in phage-resistant Klebsiella pneumoniae entail cross-phage sensitization and loss of multidrug resistance.
Bacteriophage therapy is currently being evaluated as a critical complement to traditional antibiotic treatment. However, the emergence of phage resistance is perceived as a major hurdle to the sustai...
- Drug Synergy Prediction via Residual Graph Isomorphism Networks and Attention Mechanisms
In the treatment of complex diseases, treatment regimens using a single drug often yield limited efficacy and can lead to drug resistance. In contrast, combination drug therapies can significantly imp...
- Characterization of the novel transposon Tn7722 harboring bla NDM-1 : Insights into the evolutionary dynamics of resistance in Klebsiella pneumoniae
Background: Klebsiella pneumoniae is a major opportunistic pathogen responsible for various invasive infections. The rise of carbapenem-resistant K. pneumoniae, primarily due to acquisition of bla NDM...
- Time-Varying Hazard Patterns and Co-Mutation Profiles of KRAS G12C and G12D in Real-World NSCLC
Background: KRAS mutations are the largest oncogenic subset in NSCLC. While KRAS G12C is now targetable, no approved therapies exist for G12D. We examined time-to-next-treatment (TTNT) and overall sur...
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.